1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Bavituximab (Primary) ; Pembrolizumab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 31 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2023 Planned End Date changed from 1 Jan 2025 to 1 Jan 2027.
- 21 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2025.